| 徐威,曾智,詹娜,等.肺癌早期筛查与分子标志物[J].中国临床保健杂志,2020,23(2):285-288. |
| 肺癌早期筛查与分子标志物 |
| Early screening of lung cancer and molecular markers |
| 投稿时间：2019-08-23 |
| DOI：10.3969/J.issn.1672-6790.2020.02.037 |
| 中文关键词: 肺肿瘤 生物标记 癌症早期检测 抗体 综述 |
| 英文关键词: Lung neoplasms Biomarkers Early detection of cancer Antibodies Review 〖FL |
| 基金项目: |
|
| 摘要点击次数: 5436 |
| 全文下载次数: 6232 |
| 中文摘要: |
| 肺癌是导致中国癌症死亡的首要原因。已有的研究证明低剂量螺旋CT对肺癌高危人群进行肺癌筛查能降低20%的肺癌死亡。基于肿瘤免疫应答机制的肺癌7种自身抗体被证实能通过血液检测发现早期肺癌。《中国肺癌低剂量螺旋CT筛查指南(2018年版)》与“2017年美国胸科医师学会专家共识”都指出,分子标志物肺癌7项抗体与低剂量螺旋CT(LDCT)筛查的联合应用是未来全球肺癌筛查的方向；分子标志物有助于鉴别因肺癌LDCT筛查获益的肺癌高危人群,分子标志物及其与LDCT筛查的联合应用可能降低过高的假阳性结果；同时,肺癌7项抗体分子生物标志物还可以协助临床鉴定不确定的肺结节。 |
| 英文摘要: |
| Lung cancer is the leading cause of cancer-related deaths in China.Low-dose computed tomography (LDCT) screening is recommended in US for the early detection of lung cancer in patients at high risk,and this procedure has demonstrated a reduction in mortality of 20%.Based on the immunoediting theory,tumor-specific antigens are captured by the immune system and lead to the formation of autoantibodies (AABs) via humoral immune responses.The diagnostic value of a panel in lung cancer was widely validated.Chinese LDCT screening guidelines (version 2018) and the 2017 American Thoracic Association point out that LDCT combined with biomarkers,is needed to optimize the approach to low-dose CT screening in the future.Molecular markers can help to identify the high risk groups of lung cancer and reduce the cost of screening and the risk associated with screening.The molecular markers panel improved PPV and reduced the false-positivity rate with LDCT screening.Taken together,molecular markers(7-AABs panel) showes robust potential for the early diagnosis of lung cancer and uncertain pulmonary nodules,suggesting that it should be further implemented inclinical practice by comparing the feasibility and benefit of CT and The 7-AABs panel against lung cancer in the detection of early lung cancer in chinese physical examination population. |
|
查看全文
|
| 关闭 |
|
|
|